[Preliminary clinical evaluation of unasyn preparation in genitourinary tract infections].
The preparation Unasyn Pfizer in tablets of 375 mg was used for 10 days in doses of 1 tablet twice daily in 31 patients of either sex with chronic genitourinary tract infection. For criterion of treatment efficacy, the lack of significant bacteriuria was accepted as well as regression of leukocyturia and clinical signs of infection. Cure was achieved in 24 patients, improvement was found in five patients, and the lack of therapeutic effect was observed in two cases. Unasyn is useful in the treatment of genitourinary tract infections, especially by Escherichia coli and Proteus species, and is convenient in dosage, non-toxic, and well tolerated by patients.
Dutkiewicz
S
S
Kliniki Urologii Centralnego Szpitala Klinicznego MSW, Warszawie.
Kuźnik
Z
Z
Tarasiewicz
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy*; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases; D008875:Middle Aged; D013407:Sulbactam / Q000627:therapeutic use*; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy*
C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam
Wstepna ocena kliniczna preparatu unasyn w zakazeniach układu moczowo-płciowego.